This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (1311)  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in JAMA  Topic Collections  • Rheumatology  • Osteoporosis  • Randomized Controlled Trial  • Alert me on articles by topic  Social Bookmarking   What's this?

Results From a 3-Year Randomized Clinical Trial

Bruce Ettinger, MD; Dennis M. Black, PhD; Bruce H. Mitlak, MD; Ronald K. Knickerbocker, PhD; Thomas Nickelsen, MD; Harry K. Genant, MD; Claus Christiansen, MD; Pierre D. Delmas, MD, PhD; Jose R. Zanchetta, MD; Jacob Stakkestad, MD; Claus C. Glüer, PhD; Kathryn Krueger, MD; Fredric J. Cohen, MD; Stephen Eckert, PhD; Kristine E. Ensrud, MD, MPH; Louis V. Avioli, MD; Paul Lips, MD, PhD; Steven R. Cummings, MD; for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

JAMA. 1999;282:637-645.

Context  Raloxifene hydrochloride, a selective estrogen receptor modulator, prevents bone loss in postmenopausal women, but whether it reduces fracture risk in these women is not known.

Objective  To determine the effect of raloxifene therapy on risk of vertebral and nonvertebral fractures.

Design  The Multiple Outcomes of Raloxifene Evaluation (MORE) study, a multicenter, randomized, blinded, placebo-controlled trial.

Setting and Participants  A total of 7705 women aged 31 to 80 years in 25 countries who had been postmenopausal for at least 2 years and who met World Health Organization criteria for having osteoporosis. The study began in 1994 and had up to 36 months of follow-up for primary efficacy measurements and nonserious adverse events and up to 40 months of follow-up for serious adverse events.

Interventions  Participants were randomized to 60 mg/d or 120 mg/d of raloxifene or to identically appearing placebo pills; in addition, all women received supplemental calcium and cholecalciferol.

Main Outcome Measures  Incident vertebral fracture was determined radiographically at baseline and at scheduled 24- and 36-month visits. Nonvertebral fracture was ascertained by interview at 6-month-interim visits. Bone mineral density was determined annually by dual-energy x-ray absorptiometry.

Results  At 36 months of the evaluable radiographs in 6828 women, 503 (7.4%) had at least 1 new vertebral fracture, including 10.1% of women receiving placebo, 6.6% of those receiving 60 mg/d of raloxifene, and 5.4% of those receiving 120 mg/d of raloxifene. Risk of vertebral fracture was reduced in both study groups receiving raloxifene (for 60-mg/d group: relative risk [RR], 0.7; 95% confidence interval [CI], 0.5-0.8; for 120-mg/d group: RR, 0.5; 95% CI, 0.4-0.7). Frequency of vertebral fracture was reduced both in women who did and did not have prevalent fracture. Risk of nonvertebral fracture for raloxifene vs placebo did not differ significantly (RR, 0.9; 95% CI, 0.8-1.1 for both raloxifene groups combined). Compared with placebo, raloxifene increased bone mineral density in the femoral neck by 2.1% (60 mg) and 2.4% (120 mg) and in the spine by 2.6% (60 mg) and 2.7% (120 mg) P<0.001 for all comparisons). Women receiving raloxifene had increased risk of venous thromboembolus vs placebo (RR, 3.1; 95% CI, 1.5-6.2). Raloxifene did not cause vaginal bleeding or breast pain and was associated with a lower incidence of breast cancer.

Conclusions  In postmenopausal women with osteoporosis, raloxifene increases bone mineral density in the spine and femoral neck and reduces risk of vertebral fracture.

Author Affiliations: Division of Research, Kaiser Permanente, Oakland, Calif (Dr Ettinger) and Departments of Epidemiology and Biostatistics (Drs Black and Cummings), Radiology (Dr Genant), and Medicine (Dr Cummings), University of California, San Francisco; Eli Lilly and Co, Indianapolis, Ind (Drs Mitlak, Knickerbocker, Nickelsen, Krueger, Cohen, and Eckert); Center for Clinical and Basic Research, Ballerup, Denmark (Dr Christiansen); INSERM, Lyon, France (Dr Delmas); Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina (Dr Zanchetta); Center for Clinical Osteoporosis Research CECOR AS, Haugesund, Norway (Dr Stakkestad); Department of Diagnostic Radiology, Cristian-Albrechts–Universität Kiel, Germany (Dr Glüer); Veterans Affairs Medical Center, Minneapolis, Minn (Dr Ensrud); Washington University, St Louis, Mo (Dr Avioli); and Vrije Universiteit, Amsterdam, the Netherlands (Dr Lips).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Raloxifene and Risk of Vertebral Fracture in Postmenopausal Women
J. Halbekath, W. Becker-Brüser, H. Wille, and Bruce Ettinger
JAMA. 2000;283(17):2236-2237.
EXTRACT | FULL TEXT  

Use of Alendronate After 5 Years of Treatment
Susan M. Ott
JAMA. 2007;297(18):1979.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Therapy for Fracture Prevention
Michael R. McClung
JAMA. 1999;282(7):687-689.
EXTRACT | FULL TEXT  

August 18, 1999
JAMA. 1999;282(7):701-702.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Osteoporosis Disease Management: What Every Orthopaedic Surgeon Should Know
Dell et al.
JBJS 2009;91:79-86.
FULL TEXT  

Continuous broad protection against osteoporotic fractures with strontium ranelate
Ferrari
Rheumatology (Oxford) 2009;48:iv20-iv24.
ABSTRACT | FULL TEXT  

Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer
Nelson et al.
ANN INTERN MED 2009;0:0000605-200911170-00147v1-E-147.
ABSTRACT | FULL TEXT  

Interpretation of Randomized Controlled Trials of Fracture Prevention
Nguyen
IBMS BoneKEy 2009;6:279-294.
ABSTRACT | FULL TEXT  

Trends and determinants of prescription medication use for treatment of osteoporosis
Farley and Blalock
Am J Health Syst Pharm 2009;66:1191-1201.
ABSTRACT | FULL TEXT  

Effects of Arzoxifene on Bone Mineral Density and Endometrium in Postmenopausal Women with Normal or Low Bone Mass
Bolognese et al.
J. Clin. Endocrinol. Metab. 2009;94:2284-2289.
ABSTRACT | FULL TEXT  

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction
Visvanathan et al.
JCO 2009;27:3235-3258.
ABSTRACT | FULL TEXT  

Teriparatide and Raloxifene Reduce the Risk of New Adjacent Vertebral Fractures in Postmenopausal Women with Osteoporosis. Results from Two Randomized Controlled Trials
Bouxsein et al.
JBJS 2009;91:1329-1338.
ABSTRACT | FULL TEXT  

Prediction of Changes in Bone Mineral Density in Postmenopausal Women Treated with Once-Weekly Bisphosphonates
Burnett-Bowie et al.
J. Clin. Endocrinol. Metab. 2009;94:1097-1103.
ABSTRACT | FULL TEXT  

Questioning the Accuracy of a Recent Review of Osteoporosis Medications
Kuhl et al.
ANN INTERN MED 2009;150:423-424.
FULL TEXT  

Questioning the Accuracy of a Recent Review of Osteoporosis Medications
MacLean and Suttorp
ANN INTERN MED 2009;150:424-425.
FULL TEXT  

Is Monitoring Osteoporosis Therapy Worthwhile?
Compston
IBMS BoneKEy 2009;6:99-106.
ABSTRACT | FULL TEXT  

Prevention, Diagnosis, and Management of Osteoporosis-Related Fracture
Fakih
JAOA: Journal of the American Osteopathic Association 2009;109:191-193.
FULL TEXT  

The Metabolic Syndrome and Development of Cognitive Impairment Among Older Women
Yaffe et al.
Arch Neurol 2009;66:324-328.
ABSTRACT | FULL TEXT  

Effects of the Selective Estrogen Receptor Modulator Raloxifene on Coronary Outcomes in The Raloxifene Use for the Heart Trial: Results of Subgroup Analyses by Age and Other Factors
Collins et al.
Circulation 2009;119:922-930.
ABSTRACT | FULL TEXT  

A Century of Deciphering the Control Mechanisms of Sex Steroid Action in Breast and Prostate Cancer: The Origins of Targeted Therapy and Chemoprevention
Jordan
Cancer Res. 2009;69:1243-1254.
ABSTRACT | FULL TEXT  

Medical Management of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop
Khan et al.
J. Clin. Endocrinol. Metab. 2009;94:373-381.
ABSTRACT | FULL TEXT  

New Therapies for Osteoporosis
Hegge et al.
Journal of Pharmacy Practice 2009;22:53-64.
ABSTRACT  

Differential Biochemical and Cellular Actions of Premarin Estrogens: Distinct Pharmacology of Bazedoxifene-Conjugated Estrogens Combination
Berrodin et al.
Mol. Endocrinol. 2009;23:74-85.
ABSTRACT | FULL TEXT  

Estrogen Receptor-{beta} as a Potential Target for Colon Cancer Prevention: Chemoprevention of Azoxymethane-Induced Colon Carcinogenesis by Raloxifene in F344 Rats
Janakiram et al.
Cancer Prevention Research 2009;2:52-59.
ABSTRACT | FULL TEXT  

Review Article: A New Approach to Menopausal Therapy: The Tissue Selective Estrogen Complex
Komm
Reproductive Sciences 2008;15:984-992.
ABSTRACT  

Osteoporosis
Davies
InnovAiT 2008;1:808-812.
ABSTRACT | FULL TEXT  

Tamoxifen Use and Osteoporotic Fracture Risk: A Population-Based Analysis
Cooke et al.
JCO 2008;26:5227-5232.
ABSTRACT | FULL TEXT  

Opportunities and Strategies for Breast Cancer Prevention Through Risk Reduction
Mahoney et al.
CA Cancer J Clin 2008;0:CA.2008.0016v1-CA.2008.0016.
ABSTRACT | FULL TEXT  

Fracture Prevention in Frail Older Adults: Why, When and How
Colon-Emeric
IBMS BoneKEy 2008;5:426-435.
ABSTRACT | FULL TEXT  

Osteoporosis Primer for the Vertebroplasty Practitioner: Expanding the Focus Beyond Needles and Cement
Kearns and Kallmes
Am. J. Neuroradiol. 2008;29:1816-1822.
ABSTRACT | FULL TEXT  

Prevention, Diagnosis, and Management of Osteoporosis-Related Fracture: A Multifactoral Osteopathic Approach
Gronholz
JAOA: Journal of the American Osteopathic Association 2008;108:575-585.
ABSTRACT | FULL TEXT  

Low Incidence of Anti-Osteoporosis Treatment After Hip Fracture
Rabenda et al.
JBJS 2008;90:2142-2148.
ABSTRACT | FULL TEXT  

Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians
Qaseem et al.
ANN INTERN MED 2008;149:404-415.
ABSTRACT | FULL TEXT  

Impact of Raloxifene or Tamoxifen Use on Endometrial Cancer Risk: A Population-Based Case-Control Study
DeMichele et al.
JCO 2008;26:4151-4159.
ABSTRACT | FULL TEXT  

The Effects of Tibolone in Older Postmenopausal Women
Cummings et al.
NEJM 2008;359:697-708.
ABSTRACT | FULL TEXT  

Management of breast cancer--Part I
Turner and Jones
BMJ 2008;337:a421-a421.
FULL TEXT  

Usefulness of Computer-Aided Diagnosis Schemes for Vertebral Fractures and Lung Nodules on Chest Radiographs
Kasai et al.
Am. J. Roentgenol. 2008;191:260-265.
ABSTRACT | FULL TEXT  

The Effect of Raloxifene Treatment in Postmenopausal Women with CKD
Ishani et al.
J. Am. Soc. Nephrol. 2008;19:1430-1438.
FULL TEXT  

The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancer--Survival or Death?
Jordan
JCO 2008;26:3073-3082.
ABSTRACT | FULL TEXT  

The Rise of Raloxifene and the Fall of Invasive Breast Cancer
Jordan
JNCI J Natl Cancer Inst 2008;100:831-833.
FULL TEXT  

Review of Comparative Effectiveness of Treatments to Prevent Fractures
Stock et al.
ANN INTERN MED 2008;148:885-885.
FULL TEXT  

Multidisciplinary patient education in groups increases knowledge on osteoporosis: A randomized controlled trial
Nielsen et al.
Scand J Public Health 2008;36:346-352.
ABSTRACT  

Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons
Gehrig et al.
JBJS 2008;90:1362-1374.
FULL TEXT  

Randomized Trial of Once-Weekly Parathyroid Hormone (1-84) on Bone Mineral Density and Remodeling
Black et al.
J. Clin. Endocrinol. Metab. 2008;93:2166-2172.
ABSTRACT | FULL TEXT  

Gut, inflammation and osteoporosis: basic and clinical concepts
Tilg et al.
Gut 2008;57:684-694.
ABSTRACT | FULL TEXT  

Improving Evaluation and Treatment for Osteoporosis Following Distal Radial Fractures. A Prospective Randomized Intervention
Rozental et al.
JBJS 2008;90:953-961.
ABSTRACT | FULL TEXT  

Persistent Hot Flushes in Older Postmenopausal Women
Huang et al.
Arch Intern Med 2008;168:840-846.
ABSTRACT | FULL TEXT  

ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults
MacLaughlin and Raehl
Am J Health Syst Pharm 2008;65:343-357.
FULL TEXT  

Differential Regulation of Native Estrogen Receptor-Regulatory Elements by Estradiol, Tamoxifen, and Raloxifene
Levy et al.
Mol. Endocrinol. 2008;22:287-303.
ABSTRACT | FULL TEXT  

Drugs for pre-osteoporosis: prevention or disease mongering?
Alonso-Coello et al.
BMJ 2008;336:126-129.
FULL TEXT  

Long-term Risk of Incident Vertebral Fractures
Cauley et al.
JAMA 2007;298:2761-2767.
ABSTRACT | FULL TEXT  

Relationship between Bone Mineral Density Changes and Fracture Risk Reduction in Patients Treated with Strontium Ranelate
Bruyere et al.
J. Clin. Endocrinol. Metab. 2007;92:3076-3081.
ABSTRACT | FULL TEXT  

Bone Density in Breast Cancer: When to Intervene?
Gralow
JCO 2007;25:3194-3197.
FULL TEXT  

Raloxifene Enhances Material-Level Mechanical Properties of Femoral Cortical and Trabecular Bone
Allen et al.
Endocrinology 2007;148:3908-3913.
ABSTRACT | FULL TEXT  

The role of DXA bone density scans in the diagnosis and treatment of osteoporosis
Blake and Fogelman
Postgrad. Med. J. 2007;83:509-517.
ABSTRACT | FULL TEXT  

Assessment of non-vertebral fracture risk in postmenopausal women
Roux et al.
Ann Rheum Dis 2007;66:931-935.
ABSTRACT | FULL TEXT  

Patient Assessment in the Diagnosis, Prevention, and Treatment of Osteoporosis
Lata and Elliott
Nutr Clin Pract 2007;22:261-275.
ABSTRACT | FULL TEXT  

Review of Postmenopausal Osteoporosis Pharmacotherapy
Mayes
Nutr Clin Pract 2007;22:276-285.
ABSTRACT | FULL TEXT  

Altered Ovarian Function Affects Skeletal Homeostasis Independent of the Action of Follicle-Stimulating Hormone
Gao et al.
Endocrinology 2007;148:2613-2621.
ABSTRACT | FULL TEXT  

Use of Alendronate After 5 Years of Treatment
Ott
JAMA 2007;297:1979-1979.
FULL TEXT  

Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black et al.
NEJM 2007;356:1809-1822.
ABSTRACT | FULL TEXT  

SERMs: Meeting the Promise of Multifunctional Medicines
Jordan
JNCI J Natl Cancer Inst 2007;99:350-356.
ABSTRACT | FULL TEXT  

Twenty-Year Follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial
Powles et al.
JNCI J Natl Cancer Inst 2007;99:283-290.
ABSTRACT | FULL TEXT  

Selective Activation of Estrogen Receptor-{beta} Transcriptional Pathways by an Herbal Extract
Cvoro et al.
Endocrinology 2007;148:538-547.
ABSTRACT | FULL TEXT  

Osteoporosis and its management
Poole and Compston
BMJ 2006;333:1251-1256.
FULL TEXT  

A 55-Year-Old Woman With Osteopenia
Cummings
JAMA 2006;296:2601-2610.
ABSTRACT | FULL TEXT  

Effect of raloxifene on salivary sex steroid concentrations in premenopausal women
Chatterton et al.
J Endocrinol 2006;191:599-604.
ABSTRACT | FULL TEXT  

Osteoporosis Redux
Lentle and Worsley
JNM 2006;47:1945-1959.
FULL TEXT  

Commentary on Mobley and Others: Importance of Assumptions About VTE Mortality in Modeling the Cost-effectiveness of Osteoporosis Therapies
Meadows et al.
Med Decis Making 2006;26:633-635.
 

Clinical Applications of Vertebral Fracture Assessment by Dual-Energy X-Ray Absorptiometry
Lewiecki and Laster
J. Clin. Endocrinol. Metab. 2006;91:4215-4222.
ABSTRACT | FULL TEXT  

Skeletal complications of breast cancer therapies.
Hirbe et al.
Clin. Cancer Res. 2006;12:6309s-6314s.
ABSTRACT | FULL TEXT  

Treatment-related osteoporosis in men with prostate cancer.
Smith
Clin. Cancer Res. 2006;12:6315s-6319s.
ABSTRACT | FULL TEXT  

Effect of Raloxifene on the Incidence of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis Categorized by Breast Cancer Risk
Lippman et al.
Clin. Cancer Res. 2006;12:5242-5247.
ABSTRACT | FULL TEXT  

Hemodynamic effects of acute and repeated exposure to raloxifene in ovariectomized sheep
Zoma et al.
Am. J. Physiol. Heart Circ. Physiol. 2006;291:H1216-H1225.
ABSTRACT | FULL TEXT  

Does Vertebroplasty Cause Incident Vertebral Fractures? A Review of Available Data
Trout and Kallmes
Am. J. Neuroradiol. 2006;27:1397-1403.
ABSTRACT | FULL TEXT  

Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO)
Jakob et al.
QJM 2006;99:531-543.
ABSTRACT | FULL TEXT  

Preventing fragility hip fracture in high risk groups: an opportunity missed.
Peng et al.
Postgrad. Med. J. 2006;82:528-531.
ABSTRACT | FULL TEXT  

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
Barrett-Connor et al.
NEJM 2006;355:125-137.
ABSTRACT | FULL TEXT  

Risk-benefit profiles of raloxifene for women.
Stefanick
NEJM 2006;355:190-192.
FULL TEXT  

Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
Vogel et al.
JAMA 2006;295:2727-2741.
ABSTRACT | FULL TEXT  

Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
Land et al.
JAMA 2006;295:2742-2751.
ABSTRACT | FULL TEXT  

Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward
Kelloff et al.
Clin. Cancer Res. 2006;12:3661-3697.
ABSTRACT | FULL TEXT  

The Cost-effectiveness of Therapy With Teriparatide and Alendronate in Women With Severe Osteoporosis.
Liu et al.
Arch Intern Med 2006;166:1209-1217.
ABSTRACT | FULL TEXT  

Meta-analysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis.
Nayak et al.
ANN INTERN MED 2006;144:832-841.
ABSTRACT | FULL TEXT  

Linking Ligand-Induced Alterations in Androgen Receptor Structure to Differential Gene Expression: A First Step in the Rational Design of Selective Androgen Receptor Modulators
Kazmin et al.
Mol. Endocrinol. 2006;20:1201-1217.
ABSTRACT | FULL TEXT  

Diagnosis, Screening, Prevention, and Treatment of Osteoporosis
Mauck and Clarke
Mayo Clin Proc. 2006;81:662-672.
ABSTRACT | FULL TEXT  

Venous thrombosis and conjugated equine estrogen in women without a uterus.
Curb et al.
Arch Intern Med 2006;166:772-780.
ABSTRACT | FULL TEXT  

Cancer-treatment-induced bone loss, part 2
Michaud and Goodin
Am J Health Syst Pharm 2006;63:534-546.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Osteoporosis Screening and Treatment with Hormone Replacement Therapy, Raloxifene, or Alendronate
Mobley et al.
Med Decis Making 2006;26:194-206.
ABSTRACT  

The Effect of Raloxifene after Discontinuation of Long-Term Alendronate Treatment of Postmenopausal Osteoporosis
Michalska et al.
J. Clin. Endocrinol. Metab. 2006;91:870-877.
ABSTRACT | FULL TEXT  

Glucocorticoid-Induced Bone Loss in Dermatologic Patients: An Update
Summey and Yosipovitch
Arch Dermatol 2006;142:82-90.
ABSTRACT | FULL TEXT  

Intervertebral disc height in treated and untreated overweight post-menopausal women
Baron et al.
Hum Reprod 2005;20:3566-3570.
ABSTRACT | FULL TEXT  

Tamoxifen for the Prevention of Myocardial Infarction in Humans: Preclinical and Early Clinical Evidence
Grainger and Schofield
Circulation 2005;112:3018-3024.
FULL TEXT  

Expression Profiling of Rat Femur Revealed Suppression of Bone Formation Genes by Treatment with Alendronate and Estrogen but Not Raloxifene
Helvering et al.
Mol. Pharmacol. 2005;68:1225-1238.
ABSTRACT | FULL TEXT  

Analysis off Estrogen Agonism and Antagonism of Tamoxifen, Raloxifene, and ICI182780 in Endometrial Cancer Cells: A Putative Role for the Epidermal Growth Factor Receptor Ligand Amphiregulin
Gielen et al.
Reproductive Sciences 2005;12:e55-e66.
ABSTRACT  

The prevention of osteoporotic fractures
Karlsson et al.
J Bone Joint Surg Br 2005;87-B:1320-1327.
FULL TEXT  

The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers
Rau et al.
Endocr Relat Cancer 2005;12:511-532.
ABSTRACT | FULL TEXT  

Bazedoxifene Acetate: A Selective Estrogen Receptor Modulator with Improved Selectivity
Komm et al.
Endocrinology 2005;146:3999-4008.
ABSTRACT | FULL TEXT  

Daily and Cyclic Parathyroid Hormone in Women Receiving Alendronate
Cosman et al.
NEJM 2005;353:566-575.
ABSTRACT | FULL TEXT